

IN THE CLAIMS

HUBR-1183.1-Div

Claims 1-17 (canceled)

18. (currently amended): A stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which can be degraded to 3-deazaadenosine ~~in the~~ in a body under physiological conditions.

19. (previously presented): The stent of claim 18, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

20. (previously presented): The stent of claim 18, wherein said 3-deazaadenosine or analog of 3-deazaadenosine is covalently bound to the stent.

21. (currently amended) A method of treating ~~preventing~~ in-stent restenosis, ~~or a~~ reperfusion ~~injury~~, ~~injury or treating and preventing~~ an infectious coronary syndrome, ~~or an~~ inflammatory coronary syndrome, dilated cardiomyopathy, viral myocarditis ~~or an infection by a~~ ~~parasite that causes in-stent restenosis, a~~ or a reperfusion injury ~~or an infectious or inflammatory~~ ~~coronary syndrome~~ comprising implanting the stent of claim 18 in a patient in need thereof.

22. (currently amended): The method of claim 21, wherein in-stent restenosis is treated ~~prevented~~.

Claims 23-25 (canceled)

26. (previously presented) The stent of claim 18, wherein said analog of deazaadenosine is 3-deazaadenosine-3'-monophosphoric acid.

27. (previously presented) The stent of claim 18, wherein said analog of deazaadenosine is 3-deazaadenosine-3'5'-cyclophosphate.

28. (previously presented): The stent of claim 18, wherein said analog of deazaadenosine is 3-deazaadenosine-5'-diphosphoric acid.

29. (previously presented) The stent of claim 26, wherein said analog is covalently bound to the stent.

30. (previously presented) The stent of claim 27, wherein said analog is covalently bound to the stent. HUBR-1183.1-Div

31. (previously presented) The stent of claim 28, wherein said analog is covalently bound to the stent.

32. (currently amended) A method of treating ~~preventing~~ reperfusion injuries comprising implanting the stent of claim 18 in a patient in need thereof.

33. (previously presented) A method of treating an infectious coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

34. (currently amended) A method of treating ~~preventing~~ an infectious coronary syndrome comprising implanting the stent of claim 19 ~~18~~ in a patient in need thereof.

35. (previously presented) A method of treating an inflammatory coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

36. (previously presented) A method of preventing an inflammatory coronary syndrome comprising implanting the stent of claim 18 in a patient in need thereof.

37 (previously presented) A method of treating dilated cardiomyopathy comprising implanting the stent of claim 18 in a patient in need thereof.

38. (currently amended) A method of treating ~~preventing~~ dilated cardiomyopathy comprising implanting the stent of claim 19 ~~18~~ in a patient in need thereof.

39. (previously presented) A method of treating viral myocarditis by implanting the stent of claim 18 in a patient in need thereof.

40. (currently amended) A method of treating ~~preventing~~ viral myocarditis by implanting the stent of claim 19 ~~18~~ in a patient in need thereof.

HUBR-1183.1-Div

41. (currently amended) A method according to claim 21, wherein the method comprises treating in-stent restenosis, ~~a reperfusion injury~~, an inflammatory coronary syndrome, dilated cardiomyopathy, or viral myocarditis ~~or an infection by a parasite, that causes in-stent restenosis, a reperfusion injury, or an inflammatory coronary syndrome.~~

42. (currently amended) A method according to claim 21, wherein the method comprises treating preventing in-stent restenosis, a reperfusion injury, an inflammatory coronary syndrome, or dilated cardiomyopathy ~~cardiomyopathy, viral myocarditis or an infection by a parasite that causes in-stent restenosis, a reperfusion injury, or an inflammatory coronary syndrome.~~

43. (currently amended) The method of claim 41, wherein in-stent restenosis or viral myocarditis is treated said parasite in Malaria tropica.

44. (currently amended) The method of claim 42, wherein a reperfusion injury or an inflammatory coronary syndrome is treated wherein said parasite in Malaria tropica.